Postprandial Glucagon-like Peptide-1 (GLP-1) Response is Positively Associated with Changes in Neuronal Activity of Brain Areas Implicated in Satiety and Food Intake Regulation in Humans
Overview
Authors
Affiliations
Postprandial glucagon-like peptide-1 (GLP-1) secretion can act as a meal termination signal in animals and humans. We tested the hypothesis that the postprandial changes in plasma GLP-1 concentrations are associated with changes in the human brain activity in response to satiety by performing a post-hoc analysis of a cross-sectional study of neuroanatomical correlates of hunger and satiation using (15)O-water positron-emission tomography (PET). Forty-two subjects (22M/20F, age 31+/-8 years) spanning a wide range of adiposity (body fat: 7-44%) were included in this analysis. Outcome measures included changes in PET-measured regional cerebral blood flow (rCBF) and plasma concentrations of GLP-1, glucose, insulin, and free-fatty acids (FFA), elicited by the administration of a satiating amount of a liquid formula meal. The peak postprandial increases in plasma GLP-1 concentrations were correlated with increases in rCBF in the left dorsolateral prefrontal cortex (including the left middle and inferior frontal gyri), previously implicated in PET studies of human satiation, and the hypothalamus, previously implicated in the regulation of food intake in animal and human studies, both before and after adjustment for sex, age, body fat, and changes in plasma glucose, insulin, and serum FFA concentrations. The postprandial GLP-1 response is associated with activation of areas of the human brain previously implicated in satiation and food intake regulation.
State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis.
Wang L, Savani R, Bernabucci M, Lu Y, Singh I, Xu W Res Sq. 2024; .
PMID: 38559032 PMC: 10980146. DOI: 10.21203/rs.3.rs-3929981/v1.
Pharmacotherapy for obesity: moving towards efficacy improvement.
Coutinho W, Halpern B Diabetol Metab Syndr. 2024; 16(1):6.
PMID: 38172940 PMC: 10763391. DOI: 10.1186/s13098-023-01233-4.
Wu S, Jia W, He H, Yin J, Xu H, He C Nutrients. 2023; 15(21).
PMID: 37960222 PMC: 10648557. DOI: 10.3390/nu15214569.
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
Popoviciu M, Paduraru L, Yahya G, Metwally K, Cavalu S Int J Mol Sci. 2023; 24(13).
PMID: 37445623 PMC: 10341852. DOI: 10.3390/ijms241310449.
Current Insights into the Potential Role of fMRI in Discovering the Mechanisms Underlying Obesity.
Szmygin H, Szmygin M, Cheda M, Klobuszewski B, Drelich-Zbroja A, Matyjaszek-Matuszek B J Clin Med. 2023; 12(13).
PMID: 37445414 PMC: 10342891. DOI: 10.3390/jcm12134379.